Ezra's Notes Checked November 16, 2026
Investor Holdings

By @ezracrangle

← David Abrams, latest 13F

Keryx Biopharmaceuticals

In David Abrams's portfolio · Abrams Capital Management

Ticker KERX

Not in the portfolio as of Q3 2026. Every quarter it shows up in a Abrams Capital Management 13F, newest first.

QuarterActivitySharesWeightPriceValue
Q4 2018 Sell 0  
Q3 2018 Reduce 8% 9,108,867 0.8% $3.40 $31.0M
Q2 2018 Add 2% 9,950,055 1.0% $3.76 $37.4M
Q1 2018 No change 9,719,176 1.2% $4.09 $39.8M
Q4 2017 Add 70% 9,719,176 1.5% $4.65 $45.2M
Q3 2017 No change 5,719,176 1.6% $7.10 $40.6M
Q2 2017 No change 5,719,176 1.6% $7.23 $41.4M
Q1 2017 No change 5,719,176 1.4% $6.16 $35.2M
Q4 2016 No change 5,719,176 1.2% $5.86 $33.5M
Q3 2016 No change 5,719,176 1.5% $5.31 $30.4M
Q2 2016 No change 5,719,176 2.0% $6.62 $37.9M
Q1 2016 Add 4% 5,719,176 1.3% $4.67 $26.7M
Q4 2015 Add 10% 5,500,000 1.5% $5.05 $27.8M
Q3 2015 Buy 5,000,000 1.3% $3.52 $17.6M

Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.